Abstract：Objective To explore the clinical effect of Bifidobacterium Tetrad Viable Tablets in the treatment of secondary diarrhea in children with pneumonia.Methods Forty children with pneumonia secondary diarrhea were selected from July to December 2018,they were divided into study group (n=20)and control group (n=20)by occult random grouping method.Both groups were given montmorillonite powder,on this basis,the research group took Bifidobacterium Tetrad Live Bacterial Tablets,the therapeutic effect,relief time and safety were compared.Results The total effective rate in the study group was higher than that in the control group,the remission time of clinical symptoms(nausea,vomiting,fever and abdominal pain)was shorter than that of the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions was lower than that of the control group,but the difference had no statistical significance(P＞0.05).Conclusion Bifidobacterium Tetralogy Viable Tablets in the treatment of children with pneumonia secondary diarrhea can improve the therapeutic effect,accelerate the improvement of symptoms,reduce drug toxicity and side effects,it is worthy of clinical recommendation.
陈远革. 双歧杆菌四联活菌片治疗小儿肺炎继发性腹泻的临床效果[J]. 中国当代医药, 2019, 26(16): 177-179.
CHEN Yuan-ge. Clinical effect of Bifidobacterium Tetrad Viable Tablets in the treatment of secondary diarrhea in children with pneumonia. 中国当代医药, 2019, 26(16): 177-179.
京公网安备 11010502046607号